Brief Title
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
Official Title
The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases
Brief Summary
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.
Detailed Description
PRIMARY OBJECTIVES: I. Determine how fluorine F 18 clofarabine (18F-clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases. II. Determine whether 18F-clofarabine can be used to image patients with autoimmune and inflammatory diseases. OUTLINE: Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.
Study Phase
Early Phase 1
Study Type
Interventional
Primary Outcome
Standardized Uptake Value
Condition
Autoimmune Disease
Intervention
Computed Tomography
Study Arms / Comparison Groups
Imaging (fluorine F 18 clofarabine, PET/CT)
Description: Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Procedure
Estimated Enrollment
8
Start Date
January 25, 2016
Completion Date
April 30, 2018
Primary Completion Date
April 30, 2018
Eligibility Criteria
Inclusion Criteria: - Must be 18 years or older. - Diagnosed with an autoimmune and inflammatory disorder. Exclusion Criteria - Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge. - Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical conditions including claustrophobia.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Martin Allen-Auerbach, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02925351
Organization ID
15-001600
Secondary IDs
NCI-2016-01303
Responsible Party
Sponsor
Study Sponsor
Jonsson Comprehensive Cancer Center
Study Sponsor
Martin Allen-Auerbach, Principal Investigator, UCLA / Jonsson Comprehensive Cancer Center
Verification Date
November 2019